Adaptive Biotechnologies

Adaptive Biotechnologies Adaptive is an immune medicine company focused on translating the genetics of the adaptive immune system into clinical products to detect and treat disease.

Adaptive is at the forefront of immune-based discoveries, combining high-throughput sequencing and expert bioinformatics to profile T-cell and B-cell receptors. We bring the accuracy and sensitivity of its immunosequencing platform into laboratories around the world to drive groundbreaking research in cancer and other immune-mediated diseases. Adaptive also translates immunosequencing discoveries

into clinical diagnostics and therapeutic development to improve patient care. Community Guidelines and Terms of Use
The below guidelines are intended for use on our page. It applies to our Adaptive Biotechnologies community as well as any paid social advertising that is being run through the Adaptive corporate Facebook Ads Manager. This is the official page for Adaptive Biotechnologies. It is intended to provide a forum for patients, caregivers, advocates, customers, and those who want to learn more about Adaptive, our products and services. We encourage you to participate and share your thoughts. Because we work in a heavily regulated industry, we want to make sure that all discussion stays on topic and is appropriate for the community. In certain instances, your posts may not be published to our timeline or within any comment section associated with the Adaptive Biotechnologies profile based on the following guidelines. They may not be published if they:

Do not comply with Facebook’s Terms of Use.
- Include offensive language, inappropriate, racist, sexist or discriminatory remarks.
- Include disparaging remarks or personal attacks on other users.
- Share personal information, such as phone number, email address or home address.
- Share proprietary, confidential, sensitive, or nonpublic information.
- Promote products, offers, solicit money or attempt to recruit other community members.
- Violate any copyright or intellectual property.
- Request or offer advice on personal medical matters. Please consult your physician with any questions or concerns regarding personal matters of health and treatment.
- Contain a link without any context.
- Contain any information that is false or misleading.
- Perceived as disruptive, off topic, spam, and/or excessively repetitive. Updates to this page are managed by Adaptive Biotechnologies. Please note that any content provided on the Adaptive page is for information purposes only and is not intended to be a substitute for medical advice from a healthcare professional. Always visit or talk to a qualified healthcare professional regarding any medical condition and questions about your health and treatments. The Adaptive Facebook page contains comments posted by members of the public that/which do not reflect the views of Adaptive Biotechnologies. Adaptive Biotechnologies does not verify, approve, or endorse the comments or any information posted by visitors on this page, does not warrant their accuracy, and assumes no responsibility or liability arising from content of the page or for any error, omission, defamation, libel or slander. Caution should be used before relying on any statements or opinions expressed herein. Please visit www.adaptivebiotech.com for information on Adaptive Biotechnologies’ operations, immune medicine platform, and business areas of focus. We reserve the right to block users from this page who violate these Terms of Use. We reserve the right to remove this page and its contents at any time. Please check often for updates, as we reserve the right, at our sole discretion, to modify these Terms of Use, at any time. Your use of this page indicates your acceptance of the Terms of Use and any revisions to these terms.

What happens when models learn directly from large-scale T cell activation data? In one benchmark, a sequence-based appr...
04/29/2026

What happens when models learn directly from large-scale T cell activation data?

In one benchmark, a sequence-based approach outperformed structure-based pipelines—while running much faster. https://adaptivebio.tech/6xq

How do T-cell receptors recognize antigens—and which interactions lead to activation? New work (presented at  ) explores...
04/13/2026

How do T-cell receptors recognize antigens—and which interactions lead to activation? New work (presented at ) explores a data-driven approach using large-scale T-cell activation data. Read more:

A study accepted to ML4H 2025 explores whether sequence-based models trained on large-scale T-cell activation data can improve prediction of T cell receptor recognition, a longstanding challenge in computational immunology with implications for cancer and autoimmune disease. Predicting how T-cell re...

03/27/2026

This , hear from Allison Jacob, VP Medical Affairs, how MRD testing is informing care decisions across the myeloma journey. Adaptive is working to help bring better outcomes to people living with lymphoid malignancies.

This  , Sr. Dir. R&D Katie Husske reminds us, “each of us has something valuable to contribute—whether it’s our expertis...
03/08/2026

This , Sr. Dir. R&D Katie Husske reminds us, “each of us has something valuable to contribute—whether it’s our expertise, our time, or simply a willingness to listen.”

March is Myeloma Action Month. 🩸Taking action starts with awareness. Understanding what remains can change what comes ne...
03/03/2026

March is Myeloma Action Month. 🩸

Taking action starts with awareness. Understanding what remains can change what comes next.

This Black History Month, we’re proud to recognize Nyabuom Chuol, a Senior Clinical Services Specialist and leader of ou...
02/25/2026

This Black History Month, we’re proud to recognize Nyabuom Chuol, a Senior Clinical Services Specialist and leader of our Black Adapter Network ERG.

Through her dedication, Nyabuom has helped foster meaningful connections between our workplace and the broader community—creating spaces where Black culture is recognized, celebrated, and uplifted.

Thank you, Nyabuom, for shaping a culture of belonging that strengthens our company every day.

We’re honored to be named a recipient of the Equity 100 Award from the Human Rights Campaign Foundation’s Corporate Equa...
02/04/2026

We’re honored to be named a recipient of the Equity 100 Award from the Human Rights Campaign Foundation’s Corporate Equality Index — a national benchmark that measures corporate commitment to equity and inclusion. This recognition reflects the meaningful steps our team has taken to foster a workplace where everyone can bring their whole self to work and thrive.

We’re grateful to every team member who has helped shape a culture that celebrates diversity, advances equity, and invests in inclusion.

We’re excited to kick off the year at  . CEO Chad Robins will present on Monday, January 12 at 4:30 p.m. PT / 7:30 p.m. ...
01/07/2026

We’re excited to kick off the year at . CEO Chad Robins will present on Monday, January 12 at 4:30 p.m. PT / 7:30 p.m. ET. A live and archived webcast of the event will be available in the investors section of our website. https://adaptivebio.tech/qf0

12/29/2025

As we close out the year, we’re grateful for the curiosity, collaboration, and innovation that drive our work—and the colleagues and partners who make it possible.

12/22/2025

Reaching 100,000 unique patients tested with clonoSEQ® is more than a milestone — it represents thousands of individual journeys through diagnosis, monitoring, and treatment.

We’re honored to play a role in helping patients and their care teams make more informed decisions with clarity and confidence.

Learn more: https://adaptivebio.tech/tyz

Address

1165 Eastlake Avenue E
Seattle, WA
98109

Opening Hours

Monday 8am - 5pm
Tuesday 8am - 5pm
Wednesday 8am - 5pm
Thursday 8am - 5pm
Friday 8am - 5pm

Alerts

Be the first to know and let us send you an email when Adaptive Biotechnologies posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Adaptive Biotechnologies:

Share